CLAIMS

1. Use of an effective amount of an anti-Calcitonin Gene Related Peptide (CGRP) IgG antibody in the manufacture of a medicament for improving a most bothersome symptom (MBS) associated with migraine in a migraine patient who has vomiting associated with migraine, wherein the CGRP IgG antibody comprises:

(a) a heavy chain variable domain (VH) comprising the heavy chain complementarity-determining region (CDR) 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204; SEQ ID NO: 206; and SEQ ID NO: 208, respectively; and

(b) a light chain variable domain (VL) comprising the light chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224; SEQ ID NO: 226; and SEQ ID NO: 228, respectively.

2. The use of claim 1, wherein the anti-CGRP antibody is to be administered intravenously.

3. The use of claim 1, wherein the amount of said anti-CGRP antibody to be administered is between 100 mg and 300 mg, optionally about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, or about 300 mg.

4. The use of claim 1, wherein the anti-CGRP antibody is to be administered intravenously, further wherein the amount of said anti-CGRP antibody to be administered is between 100 mg and 300 mg, optionally about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, or about 300 mg.

5. The use of claim 1, wherein the VH comprises the polypeptide sequence of SEQ ID NO: 202 and/or the VL comprises the polypeptide sequence of SEQ ID NO: 222.

6. The use of claim 1, wherein the anti-CGRP antibody comprises the heavy chain polypeptide of SEQ ID NO: 201 or 566 and the light chain polypeptide of SEQ ID NO: 221.

7. The use of claim 6, wherein the anti-CGRP antibody consists of the heavy and light chain polypeptides.

8. The use of claim 1, wherein the patients' nausea is improved within 3 months, optionally within 1 month, from administration of said anti-CGRP antibody.

9. The use of claim 1, wherein a second dose of the anti-CGRP antibody is to be administered to the patient 10-14 weeks, optionally 11-13 weeks, further optionally about 12 weeks or about 3 months, after administration of said anti-CGRP antibody.

10. The use of claim 1, wherein the anti-CGRP antibody is to be administered to the patient every 10-14 weeks, optionally every 11-13 weeks, further optionally every 12 weeks or every 3 months.